01:16 AM EDT, 07/17/2026 (MT Newswires) -- Guard Therapeutics (GUARD.ST) said Thursday it received conditional approval to continue trading on the Nasdaq First North Growth Market. The approval would allow the clinical-stage biotechnology company to complete its recently announced reverse takeover of Disruptive Pharma. It remains subject to Guard Therapeutics publishing a company description that is substantially unchanged from the version submitted to Nasdaq during the review process. Under the transaction agreement, Guard Therapeutics will acquire Disruptive Pharma by issuing new shares in exchange for non-cash consideration comprising shares, giving it a 55% stake in Disruptive Pharma. Disruptive Pharma will subsequently become a subsidiary of Guard Therapeutics, while the combined company will be renamed Disruptive Pharma.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.